TriangleNCT01384513 · OUTCOME
Engraftment Rates
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- days
- Interval / dispersion
- Full Range
- Time frame
- 44 weeks
What was measured
Hematopoietic engraftment will be defined as: * ANC ≥ 0.5x10e9/L for at least 3 days * Platelet engraftment \>20,000 with no transfusion x 7 days.
Groups in this outcome
Treatment (Allogeneic PBSCT)
REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV over 60 minutes on days -11 to -8 and busulfan IV over 3 hours on days -10 to -9. Patients undergo TBI on day -6. Patients also receive cyclophosphamide IV over 2 hours on days -3 and -2. TRANSPLANTATION: Patients undergo DLI on day -6 and CD-34+ allogeneic PBSCT on day 0. GVHD PROPHYLAXIS: Beginning on day -1, patients receive tacrolimus IV or PO with taper beginning on day 42. Patients also receive mycophenolate mofetil IV BID on days -1 to 28. Fludarabine: Given IV Busulfan: Given IV Total Body Irradiation (TBI): 2 Gy administered as part of the conditioning regimen Donor Lymphocyte Infusion (DLI): Undergo DLI Cyclophosphamide (CY): Given IV Tacrolimus: Given IV or PO Mycophenolate mofetil: Given IV Allogeneic hematopoietic stem cell transplantation: Undergo CD34+ allogeneic PBSCT Peripheral blood stem cell transplantation (PBSCT): Undergo CD34+ allogeneic PBSCT
| Group | Source count |
|---|---|
| Treatment (Allogeneic PBSCT) | 40 |
Reported measurements
Median Neutrophil Engraftment
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Treatment (Allogeneic PBSCT) | 12 | Not reported | 9 | 14 | Not reported |
Median Platelet Engraftment
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Treatment (Allogeneic PBSCT) | 17 | Not reported | 12 | 173 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 9
- upper Limit
- 14
- value
- 12
- title
- Median Neutrophil Engraftment
- categories
- measurements
- group Id
- OG000
- lower Limit
- 12
- upper Limit
- 173
- value
- 17
- title
- Median Platelet Engraftment
- denoms
- counts
- group Id
- OG000
- value
- 40
- units
- Participants
- description
- Hematopoietic engraftment will be defined as: * ANC ≥ 0.5x10e9/L for at least 3 days * Platelet engraftment \>20,000 with no transfusion x 7 days.
- dispersion Type
- Full Range
- groups
- description
- REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV over 60 minutes on days -11 to -8 and busulfan IV over 3 hours on days -10 to -9. Patients undergo TBI on day -6. Patients also receive cyclophosphamide IV over 2 hours on days -3 and -2. TRANSPLANTATION: Patients undergo DLI on day -6 and CD-34+ allogeneic PBSCT on day 0. GVHD PROPHYLAXIS: Beginning on day -1, patients receive tacrolimus IV or PO with taper beginning on day 42. Patients also receive mycophenolate mofetil IV BID on days -1 to 28. Fludarabine: Given IV Busulfan: Given IV Total Body Irradiation (TBI): 2 Gy administered as part of the conditioning regimen Donor Lymphocyte Infusion (DLI): Undergo DLI Cyclophosphamide (CY): Given IV Tacrolimus: Given IV or PO Mycophenolate mofetil: Given IV Allogeneic hematopoietic stem cell transplantation: Undergo CD34+ allogeneic PBSCT Peripheral blood stem cell transplantation (PBSCT): Undergo CD34+ allogeneic PBSCT
- id
- OG000
- title
- Treatment (Allogeneic PBSCT)
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- 44 weeks
- title
- Engraftment Rates
- type
- SECONDARY
- unit Of Measure
- days
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice